Zhang Shi-Long, Chen Chen, Rao Qian-Wen, Guo Zhe, Wang Xin, Wang Zhi-Ming, Wang Li-Shun
Minhang Hospital, Fudan University, Shanghai, China.
Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Front Oncol. 2020 May 14;10:750. doi: 10.3389/fonc.2020.00750. eCollection 2020.
The objective of our study was to investigate the epidemiologic characteristics, prognostic factors and survival in patients with primary hepatic lymphoma (PHL). PHL patients diagnosed between 1983 and 2015 were identified from the SEER database. The temporal trend in PHL incidence was assessed using joinpoint regression software. Overall survival(OS) and disease-specific survival (DSS) was evaluated using the Kaplan-Meier method and log-rank test. Univariate and multivariate Cox regression analysis was performed to identify the independent prognostic factors for OS and DSS. Nomograms to predict survival possibilities were constructed based on the identified independent prognostic factors. A total of 1,182 patients were identified with PHL. The mean age was 61.7 ± 17.1 years with a male to female of 1.6:1. Diffuse large B-cell lymphoma (59.8%) was the most common histological subtype. The incidence of PHL steadily increasing by an annual percentage change (APC) of 2.6% (95% CI 2.0-3.2, < 0.05). The 1-, 5-, and 10-year OS rates were 50.85, 39.6, and 30.4%, respectively, and the corresponding DSS rates were 55.3, 47.9, and 43.3%, respectively. Multivariate Cox regression analysis revealed that age, sex, race, marital status, histological subtype, surgery, and chemotherapy were independent prognostic factors for survival. Nomograms specifically for DLBCL were constructed to predict 1-, 5-, and 10-year OS and DSS possibility, respectively. The concordance index (C-index) and calibration plots showed the established nomograms had robust and accurate performance. PHL were rare but the incidence has been steadily increasing over the past four decades. Survival has improved in recent years. Surgery or chemotherapy could provide better OS and DSS. The established nomograms specifically for DLBCL were robust and accurate in predicting 1-, 5-, and 10-year OS and DSS.
我们研究的目的是调查原发性肝淋巴瘤(PHL)患者的流行病学特征、预后因素和生存率。从监测、流行病学和最终结果(SEER)数据库中识别出1983年至2015年间诊断的PHL患者。使用连接点回归软件评估PHL发病率的时间趋势。采用Kaplan-Meier法和对数秩检验评估总生存期(OS)和疾病特异性生存期(DSS)。进行单因素和多因素Cox回归分析,以确定OS和DSS的独立预后因素。基于确定的独立预后因素构建预测生存可能性的列线图。共识别出1182例PHL患者。平均年龄为61.7±17.1岁,男女比例为1.6:1。弥漫性大B细胞淋巴瘤(59.8%)是最常见的组织学亚型。PHL的发病率以每年2.6%的年度百分比变化(APC)稳步上升(95%CI 2.0-3.2,P<0.05)。1年、5年和10年的OS率分别为50.85%、39.6%和30.4%,相应的DSS率分别为55.3%、47.9%和43.3%。多因素Cox回归分析显示,年龄、性别、种族、婚姻状况、组织学亚型、手术和化疗是生存的独立预后因素。构建了专门针对弥漫性大B细胞淋巴瘤(DLBCL)的列线图,分别预测1年、5年和10年的OS和DSS可能性。一致性指数(C指数)和校准图显示,所建立的列线图具有可靠且准确的性能。PHL较为罕见,但在过去四十年中发病率一直在稳步上升。近年来生存率有所提高。手术或化疗可提供更好的OS和DSS。所建立的专门针对DLBCL的列线图在预测1年、5年和10年的OS和DSS方面可靠且准确。